Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
184B5 | NM | Basal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9095.026 | 1.1888 | 1.3708 | 1.0168 | |
184B5 | NM | Basal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9095.026 | 1.2557 | 1.5020 | 1.0168 | |
600MPE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9118.006 | 0.9567 | 0.9218 | 1.1089 | |
600MPE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7791.018 | 1.0373 | 1.0875 | 0.8558 | |
600MPE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7791.018 | 1.0127 | 1.0298 | 0.8558 | |
SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9878.006 | 0.9851 | 0.9786 | 1.3968 | |
184A1 | NM | Basal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7787.018 | 0.9365 | 0.6821 | 0.3791 |